Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment
IntroductionThe combination of FOLFOX and bevacizumab (FOLFOX-Bev) is a promising treatment for advanced colorectal cancer (CRC). However, the response of the tumor microenvironment to FOLFOX-Bev is still largely unexplored.MethodsWe conducted single-cell transcriptomic analysis of CRC samples deriv...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1219642/full |
| _version_ | 1797770241192755200 |
|---|---|
| author | Meiling Yang Meiling Yang Ciqiu Yang Dong Ma Zijun Li Wei Zhao Wei Zhao Wei Zhao Dongyang Yang |
| author_facet | Meiling Yang Meiling Yang Ciqiu Yang Dong Ma Zijun Li Wei Zhao Wei Zhao Wei Zhao Dongyang Yang |
| author_sort | Meiling Yang |
| collection | DOAJ |
| description | IntroductionThe combination of FOLFOX and bevacizumab (FOLFOX-Bev) is a promising treatment for advanced colorectal cancer (CRC). However, the response of the tumor microenvironment to FOLFOX-Bev is still largely unexplored.MethodsWe conducted single-cell transcriptomic analysis of CRC samples derived from a patient before and after treatment to gain insights into the cellular changes associated with FOLFOX-Bev treatment.ResultsWe found that cancer cells with high proliferative, metastatic, and pro-angiogenic properties respond better to FOLFOX-Bev treatment. Moreover, FOLFOX-Bev enhances CD8+ T cell cytotoxicity, thereby boosting the anti-tumor immune response. Conversely, FOLFOX-Bev impairs the functionality of tumor-associated macrophages, plasma cells, and cancer-associated fibroblasts, leading to a decrease in VEGFB-mediated angiogenesis. Furthermore, FOLFOX-Bev treatment reset intercellular communication, which could potentially affect the function of non-cancer cells.DiscussionOur findings provide valuable insights into the molecular mechanisms underlying the response of advanced CRC to FOLFOX-Bev treatment and highlight potential targets for improving the efficacy of this treatment strategy. |
| first_indexed | 2024-03-12T21:20:26Z |
| format | Article |
| id | doaj.art-0b9048a61a2b4d96810e7688b487e27d |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T21:20:26Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-0b9048a61a2b4d96810e7688b487e27d2023-07-28T20:07:19ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-07-011310.3389/fonc.2023.12196421219642Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatmentMeiling Yang0Meiling Yang1Ciqiu Yang2Dong Ma3Zijun Li4Wei Zhao5Wei Zhao6Wei Zhao7Dongyang Yang8Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, ChinaMedical Research Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, ChinaDepartment of Breast Cancer, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, ChinaMedical Oncology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, ChinaGuangdong Provincial Institute of Geriatrics, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, ChinaGuangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, ChinaMedical Research Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, ChinaKey Laboratory of Stem Cells and Tissue Engineering (Sun Yat-Sen University), Ministry of Education, Guangzhou, ChinaMedical Oncology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, ChinaIntroductionThe combination of FOLFOX and bevacizumab (FOLFOX-Bev) is a promising treatment for advanced colorectal cancer (CRC). However, the response of the tumor microenvironment to FOLFOX-Bev is still largely unexplored.MethodsWe conducted single-cell transcriptomic analysis of CRC samples derived from a patient before and after treatment to gain insights into the cellular changes associated with FOLFOX-Bev treatment.ResultsWe found that cancer cells with high proliferative, metastatic, and pro-angiogenic properties respond better to FOLFOX-Bev treatment. Moreover, FOLFOX-Bev enhances CD8+ T cell cytotoxicity, thereby boosting the anti-tumor immune response. Conversely, FOLFOX-Bev impairs the functionality of tumor-associated macrophages, plasma cells, and cancer-associated fibroblasts, leading to a decrease in VEGFB-mediated angiogenesis. Furthermore, FOLFOX-Bev treatment reset intercellular communication, which could potentially affect the function of non-cancer cells.DiscussionOur findings provide valuable insights into the molecular mechanisms underlying the response of advanced CRC to FOLFOX-Bev treatment and highlight potential targets for improving the efficacy of this treatment strategy.https://www.frontiersin.org/articles/10.3389/fonc.2023.1219642/fulladvanced colorectal cancersingle-cell transcriptomic analysisFOLFOXbevacizumabVEGF |
| spellingShingle | Meiling Yang Meiling Yang Ciqiu Yang Dong Ma Zijun Li Wei Zhao Wei Zhao Wei Zhao Dongyang Yang Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment Frontiers in Oncology advanced colorectal cancer single-cell transcriptomic analysis FOLFOX bevacizumab VEGF |
| title | Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment |
| title_full | Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment |
| title_fullStr | Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment |
| title_full_unstemmed | Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment |
| title_short | Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment |
| title_sort | single cell analysis reveals cellular reprogramming in advanced colon cancer following folfox bevacizumab treatment |
| topic | advanced colorectal cancer single-cell transcriptomic analysis FOLFOX bevacizumab VEGF |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1219642/full |
| work_keys_str_mv | AT meilingyang singlecellanalysisrevealscellularreprogramminginadvancedcoloncancerfollowingfolfoxbevacizumabtreatment AT meilingyang singlecellanalysisrevealscellularreprogramminginadvancedcoloncancerfollowingfolfoxbevacizumabtreatment AT ciqiuyang singlecellanalysisrevealscellularreprogramminginadvancedcoloncancerfollowingfolfoxbevacizumabtreatment AT dongma singlecellanalysisrevealscellularreprogramminginadvancedcoloncancerfollowingfolfoxbevacizumabtreatment AT zijunli singlecellanalysisrevealscellularreprogramminginadvancedcoloncancerfollowingfolfoxbevacizumabtreatment AT weizhao singlecellanalysisrevealscellularreprogramminginadvancedcoloncancerfollowingfolfoxbevacizumabtreatment AT weizhao singlecellanalysisrevealscellularreprogramminginadvancedcoloncancerfollowingfolfoxbevacizumabtreatment AT weizhao singlecellanalysisrevealscellularreprogramminginadvancedcoloncancerfollowingfolfoxbevacizumabtreatment AT dongyangyang singlecellanalysisrevealscellularreprogramminginadvancedcoloncancerfollowingfolfoxbevacizumabtreatment |